Analyst Price Target

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Banorte's Shifting Price Targets Signal Renewed Market Scrutiny

A revised analyst price target for Grupo Financiero Banorte (BMV:GFNORTE O) is refocusing investor attention on the Mexican banking giant, highlighting how evolving assessments of risk and growth potential can rapidly reshape a stock's narrative.

Feb 2, 2026

Business

Seaport Research Trims Badger Meter Price Target Amid Slower Growth, Maintains Buy Rating

Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.

Feb 2, 2026

Business

Analysts Reset Dexterra Group Target: A Signal or Noise for Investors?

A recent adjustment to Dexterra Group's price target by analysts, issued without detailed rationale, has stirred debate among market watchers. The move prompts a closer look at the underlying factors that may be influencing valuation models for the facilities management and workforce accommodation provider.

Feb 2, 2026

Business

Citi Lifts Bristol-Myers Squibb Price Target, Citing Improved Biopharma Outlook Through 2026

Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.

Jan 30, 2026

Business

Argus Boosts Sanmina Price Target to $200, Citing Strong Earnings and Resilient Operations

Analyst firm Argus has raised its price target for Sanmina Corporation (SANM) to $200, maintaining a Buy rating following the company's better-than-expected Q1 2026 results and robust positioning in key growth markets.

Jan 30, 2026

Business

Kanzhun Limited (BZ) Capital Restructuring Fuels Analyst Optimism, With Price Targets Pointing to Over 40% Gain

Following a strategic adjustment to its share capital structure, China's leading online recruitment platform Kanzhun Limited sees sustained bullish sentiment from Wall Street, with a majority of analysts maintaining Buy ratings and forecasting significant upside.

Jan 30, 2026

Business

Geron Sees Price Target Cut to $3 by TD Cowen Ahead of Q4, But Buy Rating Stays

Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.

Jan 30, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

Analysts Trim Targets but See Steady Growth Ahead for Abbott Laboratories

Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.

Jan 30, 2026

Business

Diana Shipping (DSX) in the Spotlight: How Revised Analyst Targets Are Redefining the Investment Narrative

A wave of updated price targets from Wall Street analysts is prompting investors to reassess Diana Shipping Inc. The shifting forecasts reflect changing views on dry bulk shipping fundamentals and the company's strategic position, moving the stock's story beyond recent quarters.

Jan 30, 2026

Business

IBM's AI and Quantum Ambitions Fuel Optimism as Bank of America Lifts Price Target

Following a robust Q4 earnings beat, IBM's strategic focus on hybrid cloud, AI, and quantum computing earns a price target upgrade from Bank of America, with analysts citing improved growth and free cash flow trajectory.

Jan 30, 2026

Business

BofA Trims JD.com Price Target Amid Slower Growth Forecasts, Joins DBS in Cautious Stance

Bank of America has modestly lowered its price target on JD.com, following a similar move by DBS, as analysts revise down revenue and profit estimates for the Chinese e-commerce giant, citing weaker consumer electronics demand and scaled-back subsidy programs.

Jan 30, 2026

Business

Piper Sandler Trims Price Target for Expand Energy (EXE) Amid Shifting Natural Gas Landscape

Analysts at Piper Sandler have slightly lowered their price target for Expand Energy (EXE), the natural gas giant formed from a recent mega-merger, reflecting near-term pressures but maintaining a bullish long-term outlook for the sector.

Jan 30, 2026

Business

Truist Stands By DLocal With Price Target Hike, Eyes Strong Q4 Amid Tough Comparisons

Analysts at Truist reaffirm their Buy rating on DLocal (DLO), raising their price target to $17 ahead of the fintech firm's Q4 2025 earnings. While expecting solid results, they flag challenging year-over-year volume comparisons that may cap upside surprises.

Jan 30, 2026

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Jan 30, 2026

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Jan 30, 2026

Business

Truist Trims Landstar System Price Target to $145 Amid Earnings Disappointment

Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.

Jan 30, 2026

Business

C.H. Robinson Gets Price Target Boost to $194 as TD Cowen Cites Resilient Q4 Performance

Analysts at TD Cowen have increased their price target on logistics giant C.H. Robinson to $194, citing better-than-expected fourth-quarter results and margin resilience in a tough spot market, while maintaining a Hold rating.

Jan 30, 2026